BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 1773966)

  • 1. Nucleation time of gall bladder bile in gall stone patients: influence of bile acid treatment.
    Sahlin S; Ahlberg J; Angelin B; Reihnér E; Einarsson K
    Gut; 1991 Dec; 32(12):1554-7. PubMed ID: 1773966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucin in gall bladder bile of gall stone patients: influence of treatment with chenodeoxycholic acid and ursodeoxycholic acid.
    Sahlin S; Danielsson A; Angelin B; Reihnér E; Henriksson R; Einarsson K
    Gut; 1988 Nov; 29(11):1506-10. PubMed ID: 3209106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.
    Hussaini SH; Pereira SP; Murphy GM; Kennedy C; Wass JA; Besser GM; Dowling RH
    Gut; 1995 Jan; 36(1):126-32. PubMed ID: 7890216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of cholesterol monohydrate crystals in gallbladder and hepatic bile in man: influence of bile acid treatment.
    Sahlin S; Ahlberg J; Angelin B; Ewerth S; Nilsell K; Reihnér E; Einarsson K
    Eur J Clin Invest; 1988 Aug; 18(4):386-90. PubMed ID: 3139424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimum bile acid treatment for rapid gall stone dissolution.
    Jazrawi RP; Pigozzi MG; Galatola G; Lanzini A; Northfield TC
    Gut; 1992 Mar; 33(3):381-6. PubMed ID: 1568660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total protein content of human gallbladder bile: relation to cholesterol gallstone disease and effects of treatment with bile acids and aspirin.
    Sahlin S
    Eur J Surg; 1996 Jun; 162(6):463-9. PubMed ID: 8817223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced cholesterol metastability of hepatic bile and its further decline in gall bladder bile in patients with cholesterol gall stones.
    Nakano K; Chijiiwa K
    Gut; 1993 May; 34(5):702-7. PubMed ID: 8504975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.
    Iser JH; Maton PN; Murphy GM; Dowling RH
    Br Med J; 1978 Jun; 1(6126):1509-12. PubMed ID: 656777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with oral ursodeoxycholic and chenodeoxycholic acids: pretreatment computed tomography of the gall bladder improves gall stone dissolution efficacy.
    Walters JR; Hood KA; Gleeson D; Ellul JP; Keightley A; Murphy GM; Dowling RH
    Gut; 1992 Mar; 33(3):375-80. PubMed ID: 1568659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gall stone disease without gall stones--bile acid and bile lipid metabolism after complete gall stone dissolution.
    Ruppin DC; Murphy GM; Dowling RH
    Gut; 1986 May; 27(5):559-66. PubMed ID: 3699565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deoxycholic acid in gall bladder bile does not account for the shortened nucleation time in patients with cholesterol gall stones.
    Noshiro H; Chijiiwa K; Makino I; Nakano K; Hirota I
    Gut; 1995 Jan; 36(1):121-5. PubMed ID: 7890215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nucleation time and growth time in patients with cholesterol gallstone--factors affecting nucleation time and growth time and effect of UDCA and CDCA].
    Nomura Y
    Nihon Shokakibyo Gakkai Zasshi; 1989 May; 86(5):1103-13. PubMed ID: 2795947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones.
    Iwamura K
    Tokai J Exp Clin Med; 1982 Nov; 7(6):671-83. PubMed ID: 7184199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chenodeoxycholate and ursodeoxycholate on nucleation time in human gallbladder bile.
    Hirota I; Chijiiwa K; Noshiro H; Nakayama F
    Gastroenterology; 1992 May; 102(5):1668-74. PubMed ID: 1568577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative ultrastructural studies of gall bladder epithelium in gall stone free subjects and patients with gall stones.
    Sahlin S; Ahlberg J; Einarsson K; Henriksson R; Danielsson A
    Gut; 1990 Jan; 31(1):100-5. PubMed ID: 2318423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chenodeoxycholic acid and ursodeoxycholic acid administration on acyl-CoA: cholesterol acyltransferase activity in human liver.
    Abate N; Carubbi F; Bozzoli M; Bertolotti M; Farah I; Rosi A; Carulli N
    Ital J Gastroenterol; 1994; 26(6):287-93. PubMed ID: 7949265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting gall-stone dissolution rate during chenic acid therapy.
    Maudgal DP; Kupfer RM; Northfield TC
    Gut; 1983 Jan; 24(1):7-10. PubMed ID: 6848433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination.
    Agarwal DK; Choudhuri G; Saraswat VA; Negi TS; Kapoor VK; Saxena R
    Gut; 1994 Jan; 35(1):112-6. PubMed ID: 8307430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of response to ursodeoxycholic acid for gallstone dissolution.
    Bateson MC; Hill A; Bouchier IA
    Digestion; 1980; 20(5):358-64. PubMed ID: 7390061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism.
    Tint GS; Salen G; Shefer S
    Gastroenterology; 1986 Oct; 91(4):1007-18. PubMed ID: 3527851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.